Clinical trials: Lipemia
Hyperlipidaemia
A Study to Assess the Safety, Efficacy and Tolerability of AZD8233 Treatment in Participants With Hyperlipidaemia
AZD8233 is a PCSK9-targeted ASO for the reduction of circulating levels of LDL-C. This study aims to evaluate safety, efficacy and tolerability of AZD8233.
- Trial name
- SOLANO (NCT04964557)
- Testing
- AZD8233
- Where
- 66 sites in United States, Czechia and 6 more
- Volunteers
- 411 people
- Sponsor
- AstraZeneca
Hypercholesterolemia
Study of Evinacumab (REGN1500) in Participants With Persistent Hypercholesterolemia
The primary objective of the study is to evaluate the reduction of LDL-C by evinacumab in comparison to placebo after 16 weeks in patients with primary hypercholesterolemia (HeFH, or non-HeFH with a history of clinical ASCVD)…
- Trial name
- NCT03175367
- Testing
- Evinacumab, Background Lipid Modifying Therapy (LMT)
- Where
- 95 sites in United States, Australia and 18 more
- Volunteers
- 272 people
- Sponsor
- Regeneron Pharmaceuticals
Homozygous Familial Hypercholesterolemia (HoFH)
A Gene Therapy Study for Homozygous Familial Hypercholesterolemia (HoFH)
This first-in-human study is intended to evaluate the safety and preliminary effectiveness of AAV (Adeno-associated virus)-based liver-directed gene therapy in the treatment of adults with Homozygous Familial Hypercholesterolemia…
- Trial name
- NCT02651675
- Testing
- AAV directed hLDLR gene therapy
- Where
- 9 sites in United States, Canada and 2 more
- Volunteers
- 9 people
- Sponsor
- REGENXBIO Inc.
Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events
Study of Low-Density Lipoprotein Cholesterol (LDL-C) Reduction Using Evolocumab (AMG 145) in Japanese Patients With Advanced Cardiovascular Risk
The primary objective of the study was to evaluate the effect of 12 weeks of subcutaneous evolocumab administered every 2 weeks and once a month, compared with placebo, on percent change from baseline in LDL-C when used in…
- Trial name
- AMG145 (NCT01953328)
- Testing
- Atorvastatin, Evolocumab
- Where
- 54 sites in Japan
- Volunteers
- 409 people
- Sponsor
- Amgen
Hypercholesterolemia
Effects of Ezetimibe on the Absorption of Oxidized Cholesterol
The purpose of this study is to test the effects of Zetia™ (ezetimibe) 10 milligrams (mg) on the absorption of oxysterol into the blood following a meal containing oxysterol.
- Trial name
- NCT00794677
- Testing
- ezetimibe
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- UCSF Benioff Children's Hospital Oakland
Hypercholesterolemia
Begin With The Right Patients With Dual-Inhibition Action Therapy Through Vytorin for Newly Diagnosed Dyslipidemia Patients (0653A-172)(COMPLETED)
The purpose of this study is to determine the safety and tolerability of ezetimibe/simvastatin in patients newly diagnosed with dyslipidemia.
- Trial name
- BRAVO (NCT00654628)
- Testing
- ezetimibe (+) simvastatin
- Volunteers
- 173 people
- Sponsor
- Organon and Co
Cardiovascular Diseases
Study of the Effectiveness and Safety of Niaspan ® in the Treatment of Lipid Abnormalities in Latin America
Post-Marketing Observational study of Niaspan® tablet in accordance with each country regulations. This study will be conducted in a prospective, single-arm, multi-center format.
- Trial name
- NCT01200160
- Testing
- Niacin
- Where
- 22 sites in Colombia, Mexico and 1 more
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Abbott
Hypercholesterolemia, Atherosclerotic Cardiovascular Disease
Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmony OLE)
The purpose of this study is to see if bempedoic acid (ETC-1002) is safe and well-tolerated in patients with high cardiovascular risk and elevated LDL cholesterol that is not adequately controlled by their current therapy.
- Trial name
- NCT03067441
- Testing
- bempedoic acid
- Where
- 3 sites in United States
- Volunteers
- 1,462 people
- Sponsor
- Esperion Therapeutics, Inc.
Metabolic Diseases, Hyperlipidemias
Safety and Efficacy Study of ISIS 301012 (Mipomersen) Administration in High Risk Statin Intolerant Subjects
The purpose of this study is to determine safety and efficacy of mipomersen (ISIS 301012) in the reduction of total cholesterol, low density lipoprotein cholesterol (LDL-C), and apolipoprotein B (apoB) in high risk subjects…
- Conditions
- Metabolic Diseases, Hyperlipidemias, Metabolic Disorder, Hypercholesterolemia
- Trial name
- ASSIST (NCT00707746)
- Testing
- mipomersen
- Where
- Netherlands
- Volunteers
- 34 people
- Sponsor
- Kastle Therapeutics, LLC
Hypercholesterolemia
Cholesterol Medication Packaging Study
The purpose of the overall study is to improve medication use rates among veterans by looking at the risk factors of low-density lipoprotein cholesterol (LDL).
- Trial name
- MWV_CAPS (NCT01744977)
- Testing
- packaging
- Where
- 2 sites in United States
- Volunteers
- 240 people
- Sponsor
- Durham VA Medical Center
Hyperlipidemia, Hypertension
Medication Adherence Clinical Decision Support
More than 50% of adults treated for diabetes, hypertension, or lipid disorders have suboptimal medication adherence, a prominent barrier to continued improvement in chronic disease care in the United States.
- Conditions
- Hyperlipidemia, Hypertension, Diabetes, Medication Nonadherence
- Trial name
- ADH-Wizard (NCT03748420)
- Testing
- Adherence Intervention
- Where
- United States
- Volunteers
- 5,421 people
- Sponsor
- HealthPartners Institute
Hypercholesterolemia
A Study to Assess the Cholesterol Lowering Effect of an Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Patients With High Cholesterol and With High Cardiovascular Risk (0653A-809)(COMPLETED)
This is a multicenter study to evaluate the safety and efficacy of ezetimibe/simvastatin versus rosuvastatin in participants with high cholesterol.
- Trial name
- NCT00479713
- Testing
- ezetimibe (+) simvastatin, Comparator : rosuvastatin calcium
- Volunteers
- 618 people
- Sponsor
- Organon and Co
Lipid Disorder, Triglycerides High
Vascepa to Accelerate Lipoprotein Uptake and Elimination
This study is a Phase 1 pilot/feasibility mechanistic experiment to help clarify the mechanism of action of an EPA-rich fish oil preparation, icosapent ethyl, on lipid changes in statin-treated patients with residual…
- Conditions
- Lipid Disorder, Triglycerides High, Dyslipidemias
- Trial name
- VALUE (NCT03885661)
- Testing
- Icosapent Ethyl 1000 MG [Vascepa]
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Hyperlipidemia, Insulin Resistance
Relationship Between Insulin Resistance and Statin Induced Type 2 Diabetes, and Integrative Personal Omics Profiling
Background: There is general agreement that statin-treatment of patients to lower plasma cholesterol levels can increase the incidence of type 2 diabetes mellitus (T2D) in some individuals1-5.
- Conditions
- Hyperlipidemia, Insulin Resistance, Type 2 Diabetes
- Trial name
- NCT02437084
- Testing
- Atorvastatin
- Where
- United States
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- Stanford University
Hypertriglyceridemia
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The purpose of this study is to evaluate the efficacy and safety of volanesorsen given for 26 weeks in participants with Hypertriglyceridemia.
- Trial name
- NCT02300233
- Testing
- Volanesorsen
- Where
- 45 sites in United States, Canada and 4 more
- Volunteers
- 114 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Hyperlipidemia, Periodontitis, Gingivitis
PERIODONTAL DISEASE AND HYPERLIPIDEMIA
The investigators hypothesized that hyperlipidemia as an unfavourable levels of lipoprotein subfractions have deleterious impact on the development of periodontal infection by altering oxidative stres status of periodontal…
- Trial name
- NCT02808130
- Testing
- hyperlipidemia, periodontitis, gingivitis
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Ondokuz Mayıs University
Primary Hypercholesterolemia or Mixed Dyslipidemia
Efficacy and Safety of Inclisiran as Monotherapy in Chinese Adults With Low or Moderate ASCVD Risk and Elevated Low-density Lipoprotein Cholesterol.
The purpose of this study was to evaluate the efficacy and safety of inclisiran as a monotherapy in Chinese adults with low or moderate atherosclerotic cardiovascular disease (ASCVD) risk and elevated low-density lipoprotein…
- Trial name
- V-Mono China (NCT05888103)
- Testing
- Inclisiran
- Where
- 28 sites in China
- Volunteers
- 207 people
- Sponsor
- Novartis Pharmaceuticals
Lipid Metabolism, Inborn Errors, Hypercholesterolemia, Autosomal Dominant
Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia
The purpose of this study is to evaluate the safety and efficacy of extended dosing of mipomersen in patients with familial hypercholesterolemia on lipid-lowering therapy who have completed either the 301012-CS8 (NCT00280995) or…
- Conditions
- Lipid Metabolism, Inborn Errors, Hypercholesterolemia, Autosomal Dominant, Hyperlipidemias, Metabolic Diseases
- Trial name
- NCT00477594
- Testing
- mipomersen sodium
- Where
- 5 sites in United States
- Volunteers
- 21 people
- Sponsor
- Kastle Therapeutics, LLC
Diabetes, Hyperlipidemia, Mixed Dyslipidemia
Safety and Efficacy of Evolocumab in Combination With Statin Therapy in Adults With Diabetes and Hyperlipidemia or Mixed Dyslipidemia
The primary objective of this study was to evaluate the effect of 12 weeks of subcutaneous evolocumab (AMG 145) in combination with statin therapy (atorvastatin) on percent change from baseline in low-density lipoprotein…
- Trial name
- BERSON (NCT02662569)
- Testing
- Evolocumab, Atorvastatin
- Where
- 110 sites in United States, Argentina and 8 more
- Volunteers
- 986 people
- Sponsor
- Amgen
Lipoprotein Disorder
A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events
The main purpose of this study is to evaluate the efficacy and safety of LY3473329 in adult participants with elevated Lp(a) at high risk for cardiovascular events.
- Trial name
- KRAKEN (NCT05563246)
- Testing
- LY3473329
- Where
- 42 sites in United States, Australia and 6 more
- Volunteers
- 233 people
- Sponsor
- Eli Lilly and Company